MIT Sloan Management Review Article on In the Face of a Pandemic, Can Pharma Shift Gears?

The pharmaceutical industry’s competition-based model could be a real liability in the race to develop drugs and vaccines to combat COVID-19.

The COVID-19 pandemic may well prove to be the biggest challenge for humankind since World War II. Pharmaceutical companies will be key to fighting a disease that is bringing health care systems to their knees and sending shock waves through economies across the globe. They have the scientific know-how, the management capabilities, and the physical and technological capacities to develop treatments — and, ultimately, a vaccine against the virus.

About the Author

Markus Scholz (@scholz101) is the Endowed Chair of Corporate Governance & Business Ethics at the University of Applied Sciences for Management & Communication in Vienna and a visiting scholar at INSEAD. N. Craig Smith (@insead) is the INSEAD Chaired Professor of Ethics and Social Responsibility and the academic director of ESRI, INSEAD’s ethics and social responsibility initiative.

Learn more about MIT SMR.